Con: should asymptomatic patients with moderate-to-severe ?OSA be treated?

Andrew Vakulin, Ching Li Chai-Coetzer, R. Doug McEvoy

Source: Breathe, 15 (1) 11; 10.1183/20734735.0347-2018

Journal Issue: March

Disease area: Sleep and breathing disorders

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Andrew Vakulin, Ching Li Chai-Coetzer, R. Doug McEvoy. Con: should asymptomatic patients with moderate-to-severe ?OSA be treated?. Breathe, 15 (1) 11; 10.1183/20734735.0347-2018

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Pro: should asymptomatic patients with moderate-to-severe OSA be treated? Source: Breathe, 15 (1) 7; 10.1183/20734735.0340-2018 Year: 2019
Treatment of non-sleepy OSA patients - what are the alternatives ? Source: Annual Congress 2010 - Practical Workshop: "Treatment of non-sleepy OSA patients" Year: 2010
Mild OSAS: Is CPAP therapy actually required for these patients? Source: International Congress 2018 – From continuous positive airway pressure (CPAP) and adherence to CPAP to asthma-COPD overlap syndrome (ACOS) Year: 2018
When to treat elderly OSA patients Source: ERS Conference Year: 2015
What do patients want? Preferences for two asthma regimens in mild/moderate asthma Source: International Congress 2019 – Inhalers: adherence and preference Year: 2019
Deprescribing of inhaled corticosteroids in patients with COPD with mild or moderate airflow limitation: what do patients think? Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD Year: 2019
Con: Access to advanced therapies for severe asthma should be restricted to patients with satisfactory adherence to maintenance treatment Source: Breathe, 17 (2) 210049; 10.1183/20734735.0049-2021 Year: 2021
Treating OSAS in children Source: International Congress 2017 – ME1 Treating obstructive sleep apnoea syndrome in children Year: 2017
Only severe asthma? Source: International Congress 2019 – PG11 Severe paediatric asthma Year: 2019
Add-on omalizumab therapy for patients with severe persistent allergic (IgE-mediated) asthma: identifying which patients to treat and which patients respond Source: Eur Respir J 2006; 28: Suppl. 50, 440s Year: 2006
Phenotyping acute exacerbation of COPD: what more can we do for hospitalised patients? Source: ERJ Open Res, 7 (3) 00362-2021; 10.1183/23120541.00362-2021 Year: 2021
Group-delivered speech and language therapy for chronic refractory cough: what do patients want? Source: International Congress 2019 – Chronic cough, a1-antitrypsin deficiency and other conditions Year: 2019
Mild persistent asthma: to treat or not to treat regularly? Source: ERS Live 2007 Year: 2007
Should patients with life-threatening severe asthma be intubated? Source: Virtual Congress 2021 – PDW End of life care for the elderly asthmatic and COPD patients Year: 2021
Evolution of patients with severe asthma treated with mepolizumab Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020
Compliance for NIMV treatment in moderate and severe OSAS patients Source: Annual Congress 2012 - Clinical predictors of OSA, adherence to CPAP and psychology Year: 2012
Anti-inflammatory treatment in 5-10-year-old mildly symptomatic children with asthma: can we objectively measure the effect? Source: Eur Respir J 2001; 18: Suppl. 33, 495s Year: 2001